Dimerix Limited provided an update on the Company's activity relating to the commercial scale manufacturing of DMX-200. Commercial manufacturing capabilities secured with an FDA registered manufacturer, and demonstration batch manufacture completed Analytical methods developed and validated Commercial scale batch manufacture planned in Fiscal Year 2020. The development of Dimerix manufacturing capabilities has significantly progressed throughout the last quarter. The establishment of the commercial manufacturing process and the development of validated analytical methods for pharmaceutical grade DMX-200 is an essential component of the product development program and will support global marketing authorisations (including US FDA), commercialisation and partnering activities.